RhumbLine Advisers
FRTX

RhumbLine Advisers’s Fresh Tracks Therapeutics, Inc. Common Stock FRTX Stock Holding History

RhumbLine Advisers’s Portfolio FRTX Stock Details FRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q2 		– Sell
-21
Closed -$84K – 3079
2014
Q1 		$84K Sell
21
-1
-5% -$4.46K ﹤0.01% 2941
2013
Q4 		$81K Hold
22
– – ﹤0.01% 2977
2013
Q3 		$86K Hold
22
– – ﹤0.01% 2944
2013
Q2 		$218K Buy
+22
New +$244K ﹤0.01% 2928

Other funds holding FRTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
AI
Ariel Investments Chicago, Illinois $8.93B AUM 29.58% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TC
TFS Capital West Chester, Pennsylvania $255M AUM 32.31% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
New York State Common Retirement Fund
New York State Common Retirement Fund Albany, New York $79.3B AUM 43.63% 1-Year Est. Return
SGAM
Smith Group Asset Management Dallas, Texas $1.96B AUM 43.61% 1-Year Est. Return

RhumbLine Advisers's FRTX Position: Q2 2014 in Review

RhumbLine Advisers sold out of Fresh Tracks Therapeutics, Inc. Common Stock (FRTX) in Q2 2014, closing a stake of 21 shares — an estimated $84K sold.

RhumbLine Advisers first reported a position in FRTX in Q2 2013 and held it in 4 quarters. The position peaked at $218K in Q2 2013. 70 funds tracked by Wall St. Rank hold FRTX as of Q2 2014.

  • RhumbLine Advisers reported no remaining Fresh Tracks Therapeutics, Inc. Common Stock position as of Q2 2014 after selling out during the quarter.
  • RhumbLine Advisers sold 21 Fresh Tracks Therapeutics, Inc. Common Stock shares in Q2 2014, an estimated $84K.
  • RhumbLine Advisers first reported a position in Fresh Tracks Therapeutics, Inc. Common Stock in Q2 2013 and held it in 4 quarters.
  • RhumbLine Advisers's Fresh Tracks Therapeutics, Inc. Common Stock position peaked at $218K in Q2 2013.
  • 70 funds tracked by Wall St. Rank held Fresh Tracks Therapeutics, Inc. Common Stock as of Q2 2014.

Based on RhumbLine Advisers's 13F filing for Q2 2014, filed 6 Aug 2014.